10TH ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”

August 8-10, 2014
The Westin Pasadena
Pasadena, CA

Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center, Sacramento, CA
City of Hope Comprehensive Cancer Center
Duarte, CA
University of Southern California/
Norris Comprehensive Cancer Center
Los Angeles, CA
University of Pittsburgh Cancer Institute/UPMC
Pittsburgh, PA
Barbara Ann Karmanos Comprehensive Cancer Center (Wayne State University), Detroit, MI
Penn State Hershey Cancer Institute
(Penn State University), Hershey, PA

Program Chairs:
Primo Lara, Jr., M.D. | Edward Newman, Ph.D.

Steering Committee:
Chandra Belani, M.D. | Edward Chu, M.D.
David Gandara, M.D. | Heinz-Josef Lenz, MD, Ph.D.
Patricia LoRusso, D.O. | Robert Morgan, M.D.

Sponsored by:
THE MEDICAL EDUCATOR CONSORTIUM
**PROGRAM CHAIRS**

**Primo Lara, Jr., M.D.**
Professor of Medicine  
University of California Davis School of Medicine  
Associate Director for Translational Research  
University of California Davis Comprehensive Cancer Center

**Edward Newman, Ph.D.**
Associate Professor, Molecular Pharmacology  
Co-director, Analytical Pharmacology Core Facility  
City of Hope Comprehensive Cancer Center

**STEERING COMMITTEE**

**Chandra Belani, M.D.**
Miriam Beckner Distinguished Professor of Medicine  
Penn State Milton S. Hershey Medical Center Deputy Director  
Penn State Hershey Cancer Institute

**Edward Chu, M.D.**
Professor and Chief of Hematology/Oncology  
University of Pittsburgh School of Medicine  
Deputy Director, University of Pittsburgh Cancer Institute

**David Gandara, M.D.**
Professor of Medicine  
University of California Davis School of Medicine  
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

**Heinz-Josef Lenz, M.D., Ph.D.**
Professor of Medicine and Preventive Medicine, Section Head of GI Oncology  
University of Southern California, Keck School of Medicine  
Associate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

**Shirish Gadgeel, M.D.**
Leader, Thoracic Oncology Multidisciplinary Team, Barbara Ann Karmanos Cancer Center  
Associate Professor, Wayne State University School of Medicine

**DISTINGUISHED FACULTY**

**Leonard Appleman, M.D.**
Assistant Professor  
University of Pittsburgh School of Medicine  
University of Pittsburgh Cancer Institute

**Chandra Belani, M.D.**
Miriam Beckner Distinguished Professor of Medicine  
Penn State Milton S. Hershey Medical Center Deputy Director  
Penn State Hershey Cancer Institute

**Suzette Blanchard, Ph.D.**
Assistant Professor and Senior Biostatistician  
City of Hope Comprehensive Cancer Center

**Alice Chen, M.D.**
Senior Investigator  
CTEP National Cancer Institute

**Helen Chew, M.D.**
Professor of Medicine  
University of California Davis School of Medicine

**Diana Chingos, MS, MFA**
Patient Advocate  
University of Southern California and Young Survival Coalition

**Tanya Dorff, M.D.**
Assistant Professor  
University of Southern California Keck School of Medicine  
Norris Comprehensive Cancer Center

**Anthony El-Khoueiry, M.D.**
Assistant Professor  
University of Southern California Keck School of Medicine  
Norris Comprehensive Cancer Center

**Stephen Forman, M.D.**
Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation Co-leader, Hematologic Malignancies Program  
City of Hope Comprehensive Cancer Center

**Paul Frankel, Ph.D.**
Senior Biostatistician, Division of Biostatistics, Department of Information Sciences  
Beckman Research Institute, City of Hope Comprehensive Cancer Center

**Susan Groshen, Ph.D.**
Professor of Medicine and Director, Biostatistics Core  
University Southern California Norris Comprehensive Cancer Center

**Elisabeth Heath, M.D.**
Associate Professor of Oncology, Wayne State University School of Medicine  
Barbara Ann Karmanos Cancer Center

**Brian Jonas, M.D., Ph.D.**
Assistant Professor, University of California Davis School of Medicine  
University of California Davis Comprehensive Cancer Center

**Monica Joshi, M.D.**
Assistant Professor  
Penn State University Hershey School of Medicine, Penn State Hershey Cancer Institute

**Karen Kelly, M.D.**
Professor of Medicine, University of California Davis School of Medicine  
Associate Director of Clinical Research, University of California Davis Comprehensive Cancer Center

**Friedrich Knollman, M.D., Ph.D.**
Professor of Clinical Radiology, University of California Davis School of Medicine

**Marianna Koczywas, M.D.**
Clinical Professor of Medicine  
City of Hope Comprehensive Cancer Center

**Primo Lara, Jr., M.D.**
Professor of Medicine, University of California Davis School of Medicine  
Associate Director for Translational Research, University of California Davis Comprehensive Cancer Center
**COURSE DESCRIPTION**

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

**EDUCATIONAL OBJECTIVES**

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.
- Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

**TARGET AUDIENCE**

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

**NEEDS ASSESSMENT**

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently improve patient outcomes.

**ACCREDITATION**

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT HOURS**

The Medical Educator Consortium designates this educational activity for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**DISCLOSURE**

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

**NURSING CONTINUING MEDICAL EDUCATION**

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
**10th Annual California Cancer Consortium Conference**  
“Recent Advances and New Directions in Cancer Therapy”  
**FRIDAY, AUGUST 8TH, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 am - 12:30 pm</td>
<td>Industry Advisory Board Block (by invitation only)</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Registration &amp; Visit Exhibits</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>3:35 pm</td>
<td>Pre-session Survey</td>
</tr>
</tbody>
</table>

**Session 1: Inhibition of Signal Transduction and Angiogenesis Pathways**  
Chairs: Primo Lara Jr., M.D., (UC Davis) and Edward Newman, Ph.D., (City of Hope)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40 pm</td>
<td>EGFR and Met Inhibitors: State of the Art</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>3:55 pm</td>
<td>PI3K/Akt and Related Pathways: Novel Therapeutics</td>
</tr>
<tr>
<td>4:05 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>4:10 pm</td>
<td>FGF and FGFR as Therapeutic Targets</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>4:25 pm</td>
<td>New Vascular/Angiogenesis -Targeted Therapies</td>
</tr>
<tr>
<td>4:35 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>4:40 pm</td>
<td>mTOR inhibitors: Latest and Greatest</td>
</tr>
<tr>
<td>4:50 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Refreshment Break &amp; Visit Exhibits</td>
</tr>
</tbody>
</table>

**Session 2: Clinical Trial Design**  
Chairs: Jeffrey Longmate, Ph.D., (City of Hope) and Paul Frankel, Ph.D., (City of Hope)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:15 pm</td>
<td>Integration of New Clinical Trial Designs for Early Drug Development</td>
</tr>
<tr>
<td>5:25 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>5:35 pm</td>
<td>Statistical Designs for Biomarker Development</td>
</tr>
<tr>
<td>5:45 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>5:55 pm</td>
<td>Rebiopsies and Serial Biopsies in Clinical Trials</td>
</tr>
<tr>
<td>6:05 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>6:10 pm</td>
<td>Cancer Imaging in the Molecular-Targeted Era</td>
</tr>
<tr>
<td>6:20 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>6:25 pm</td>
<td>Roundtable Discussion: Novel Paradigms in Early Drug Development</td>
</tr>
</tbody>
</table>

**Roundtable Discussion: Novel Paradigms in Early Drug Development**  
Moderator: Jeffrey Longmate, Ph.D., City of Hope  
Participants: Edward Newman, Ph.D., Paul Frankel, Ph.D., Suzette Blanchard, Ph.D., Susan Grosben, Ph.D., David Gandara, M.D.

**Themes:**  
1. Phase 0 Trials  
2. Molecular Enrichment Strategies  
3. Cytostatic Therapy Assessment

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>6:50 pm</td>
<td>Post-session Survey</td>
</tr>
<tr>
<td>7:00 pm - 9:00 pm</td>
<td>Wine and Cheese Welcome Reception &amp; Visit Exhibits</td>
</tr>
</tbody>
</table>
### Session 3: Cancer Immunotherapy
**Chairs:** Chandra Belani, M.D., (Penn State) and Tianhong Li, M.D., Ph.D., (UC Davis)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10 am</td>
<td>Genetically Modified T Cells for Treatment of Cancer</td>
<td>Stephen Forman, M.D.</td>
<td>City of Hope</td>
</tr>
<tr>
<td>8:25 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 am</td>
<td>PD-1 and PDL-1 Targeted Therapy</td>
<td>Karen Kelly, M.D.</td>
<td>UC Davis</td>
</tr>
<tr>
<td>8:40 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45 am</td>
<td>Vaccine and Dendritic Cell Approaches</td>
<td>Przemyslaw Twardowski, M.D.</td>
<td>City of Hope</td>
</tr>
<tr>
<td>8:55 am</td>
<td>Question and Answer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>PD-1 and PDL-1 Targeted Therapy</td>
<td>Elisabeth Heath, M.D.</td>
<td>Wayne State</td>
</tr>
<tr>
<td>9:10 am</td>
<td>Question and Answer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 4: Lung Cancer
**Chairs:** Mariana Koczywas, M.D., (City of Hope) and Jonathan Riess, M.D., (UC Davis)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20 am</td>
<td>Linking Molecular Biology to Cancer Therapeutics in NSCLC</td>
<td>David Gandara, M.D.</td>
<td>UC Davis</td>
</tr>
<tr>
<td>9:40 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 am</td>
<td>Squamous Cell Lung Cancer: Current and Future Directions</td>
<td>Chandra Belani, M.D.</td>
<td>Penn State</td>
</tr>
<tr>
<td>10:05 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10 am</td>
<td>Small Cell Lung Cancer: Emerging Therapeutics</td>
<td>Shirish Gadgeel, M.D.</td>
<td>Wayne State</td>
</tr>
<tr>
<td>10:20 am</td>
<td>Question and Answer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:25 am</td>
<td>Refreshment Break &amp; Visit Exhibits</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 5: Gastrointestinal Malignancies
**Chairs:** Thomas Semrad, M.D., (UC Davis) and Anthony El-Khouteiri, M.D., (USC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 am</td>
<td>Keynote Lecture: Novel Approaches to the Treatment of Colorectal Carcinoma</td>
<td>Heinz-Josef Lenz, M.D., Ph.D.</td>
<td>USC</td>
</tr>
<tr>
<td>11:05 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10 am</td>
<td>New Developments in Pancreatic Cancer</td>
<td>Philip Philip, M.D.</td>
<td>Wayne State</td>
</tr>
<tr>
<td>11:25 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 6: Hematologic Malignancies
**Chair:** Brian Jonas, M.D., Ph.D., (UC Davis)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am</td>
<td>Drug Development in Lymphoid Malignancies: Implications for Personalized Therapy</td>
<td>Tanya Siddiqi, M.D.</td>
<td>City of Hope</td>
</tr>
<tr>
<td>11:50 am</td>
<td>Question-and-Answer Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 am</td>
<td>Non-Hodgkin Lymphoma: Current and Future Directions</td>
<td>Joseph Tuscano, M.D.</td>
<td>UC Davis</td>
</tr>
</tbody>
</table>
### Session 7: Genitourinary Malignancies  
**Chairs:** Przemyslaw Twardowski, M.D., (City of Hope), Monica Joshi, M.D., (Penn State)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 pm</td>
<td>Updates on Castration Resistant Prostate Cancer Therapy</td>
</tr>
<tr>
<td></td>
<td><strong>David Quinn, MBBS, Ph.D., USC</strong></td>
</tr>
<tr>
<td>1:35 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>1:40 pm</td>
<td>Updates in Renal Cell Carcinoma Drug Development</td>
</tr>
<tr>
<td></td>
<td><strong>Sumanta Pal, M.D., City of Hope</strong></td>
</tr>
<tr>
<td>1:55 pm</td>
<td>Question-and-Answer Session</td>
</tr>
</tbody>
</table>

### Session 8: Melanoma  
**Chair:** Edward Newman, Ph.D., (City of Hope)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>BRAF Inhibition in Melanoma</td>
</tr>
<tr>
<td></td>
<td><strong>Ahmad Tarbini, M.D., University of Pittsburgh</strong></td>
</tr>
<tr>
<td>2:15 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Beyond BRAF: New Innovations in Melanoma</td>
</tr>
<tr>
<td></td>
<td><strong>Kim Margolin, M.D., University of Washington</strong></td>
</tr>
<tr>
<td>2:35 pm</td>
<td>Question-and-Answer Session</td>
</tr>
</tbody>
</table>

### Session 9: Gynecologic Cancer  
**Chair:** Lynda Roman, M.D. (USC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:40 pm</td>
<td>Management of Ovarian Cancer in 2014</td>
</tr>
<tr>
<td></td>
<td><strong>Robert Morgan, M.D., City of Hope</strong></td>
</tr>
<tr>
<td>2:55 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>New Approaches to Cervix and Endometrial Cancer</td>
</tr>
<tr>
<td></td>
<td><strong>Amit Oza, M.D., Princess Margaret Hospital</strong></td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>Adjourn</td>
</tr>
<tr>
<td>3:30 – 6:30 pm</td>
<td>Industry Advisory Board Block (by invitation only)</td>
</tr>
<tr>
<td>7:30-10 pm</td>
<td>CCCP Dinner (Newman Residence)</td>
</tr>
</tbody>
</table>

### SUNDAY, AUGUST 10TH, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration, Refreshments &amp; Visit Exhibits</td>
</tr>
<tr>
<td>7:15 am – 8:00 am</td>
<td>Breakfast Symposia (non cme)</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Introduction</td>
</tr>
<tr>
<td>8:05 am</td>
<td>Pre-session Survey</td>
</tr>
</tbody>
</table>

### Session 9: Endocrine-Driven Cancers (with emphasis on Breast Cancer)  
**Chairs:** George Somlo, M.D., (City of Hope), Primo Lara, Jr., M.D., (UC Davis)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10 am</td>
<td>Keynote Lecture: New Approaches to Breast Cancer Based on Molecular Profiling</td>
</tr>
<tr>
<td></td>
<td><strong>Helen Chew, M.D., UC Davis</strong></td>
</tr>
<tr>
<td>8:25 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Prostate Cancer: Translating New Biologic Findings Into New Therapies</td>
</tr>
<tr>
<td></td>
<td><strong>Jacek Pinski, M.D., Ph.D., USC</strong></td>
</tr>
<tr>
<td>8:50 am</td>
<td>Question-and-Answer Session</td>
</tr>
</tbody>
</table>
SUNDAY, AUGUST 10TH, 2014 Continued

Session 10: Emerging Therapeutic Strategies in Oncology

8:55 am  
Keynote Lecture: New Concepts in Overcoming Drug Resistance  
TBA

9:15 am  
Question-and-Answer Session

9:20 am  
Antibody-Drug Conjugates in Solid Tumors  
Ulka Vaishampayan, M.D., Wayne State

9:35 am  
Question-and-Answer Session

9:40 am  
Antibody-Drug Conjugates and Peptibodies in Hematologic Malignancies  
Joseph Tuscano, M.D., UC Davis

9:55 am  
Question-and-Answer Session

10:00 am  
Targeting DNA Repair in Cancer Therapeutics  
Phillip Mack, Ph.D., UC Davis

10:15 am  
Question-and-Answer Session

10:20 am  
Refreshment Break & Visit Exhibits

Session 11: Integration of ‘Omics and Biomarkers into Clinical Trials and Patient Care  
Chairs: Timothy Synold, PharmD, (City of Hope), Edward Newman, Ph.D., (City of Hope)

10:30 am  
Keynote Lecture: Personalizing Cancer Therapy: The NCI Empact and Match trials  
Alice Chen, M.D., National Cancer Institute

10:45 am  
Molecular Phenotyping Platforms: What to Use and When  
Philip Mack, Ph.D., UC Davis

10:55 am  
Pharmacogenomics: Clinical Applications  
Timothy Synold, PharmD, City of Hope

11:05 am  
Circulating Tumor Cells: Relevance to Clinical Practice and Research  
Xin Liu, M.D., Penn State

11:15 am  
Roundtable Discussion and Question and Answer Session  
Theme: Best Practice Models for Biomarker and ‘Omics Technology Deployment in the Clinic and in Clinical Trials

Session 12: New Agents in Development  
Chairs: Heinz-Josef LenzM.D., Ph.D., (USC), Pat LoRusso (Wayne State)

11:30 am  
MEK inhibitors  
Monica Joshi, M.D., Penn State

11:40 am  
HSP90 inhibitors  
Anthony El-Khoueiry, M.D., USC

11:50 am  
Novel or reformulated cytotoxics (e.g., nab-paclitaxel, folate targeted agents)  
Shirish Gadgeel, M.D., Wayne State

12:00 pm  
ALK inhibitors  
Tianhong Li, M.D., Ph.D., UC Davis

12:10 pm  
Targeting epigenetics (Bromodomain inhibitors, HDAC inhibitors, etc)  
Jonathan Riess, M.D., UC Davis

12:20 pm  
Question-and-Answer Session

12:30 pm  
Adjourn
The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena’s charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of $159 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 18th, 2014, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 866.837.4181 and use group code “CA Cancer Consortium Conference”
Registration Form

Name _______________________________________________ Degree ____________________

License Number _________________________________ State______________________

Address _________________________________________________________________

Telephone (____) ____________________________ Fax (____) _____________________

Email ___________________________________________________________________

Specialty ________________________________________________________________

**TYPE OF PRACTICE:**
- [x] Private
- [ ] Academic
- [ ] Hospital
- [ ] Other

**REGISTRATION FEE:**
- [ ] $175 Physician
- [ ] $ 75 Nurse, Nurse Practitioner, Resident, Fellow, Students, Non-physician researchers and staff (e.g., CRAs)
- [ ] $250 Industry Professional
- [ ] $ 25 Per person (Saturday night dinner)

Refunds must be provided in writing prior to July 8th, 2014. A $50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

Enclosed is my check i/a/of $____________ for the registration of this conference.

I authorize MECC to charge my credit card i/a/o $____________ for the registration of this course using the following credit card.

Name as it appear on the card ________________________________ Exp. Date ____________

Card number ________________________________________________

Authorized signature _________________________________________

For those requiring special assistance, contact MECC at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2014.
“Recent Advances and New Directions in Cancer Therapy”

10TH ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

August 8-10, 2014

The Westin Pasadena, Pasadena, CA